SEARCH

SEARCH BY CITATION

References

  • 1
    Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007; 23: 415426.
  • 2
    Hoffmann C. The epidemiology of HIV coreceptor tropism. Eur J Med Res 2007; 12: 385390.
  • 3
    Sierra S, Kaiser R, Thielen A, Lengauer T. Genotypic coreceptor analysis. Eur J Med Res 2007; 12: 453462.
  • 4
    Garrido C, Roulet V, Chueca N et al. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 2008; 46: 887891.
  • 5
    McGovern RA, Thielen A, Mo T et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24: 25172525.
  • 6
    Symons J, Vandekerckhove L, Paredes R et al. Impact of triplicate testing on genotypic HIV-1 tropism prediction in routine clinical practice. Clin Microbiol Infect 2012; 18: 606612.
  • 7
    Vandekerckhove LP, Wensing AM, Kaiser R et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11: 394407.
  • 8
    Martin MP, Dean M, Smith MW et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282: 19071911.
  • 9
    Faure S, Meyer L, Costagliola D et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000; 287: 22742277.
  • 10
    McDermott DH, Colla JS, Kleeberger CA et al. Genetic polymorphism in CX3CR1 and risk of HIV disease. Science 2000; 290: 2031.
  • 11
    Fellay J, Ge D, Shianna KV et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009; 5: e1000791.
  • 12
    Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS 2004; 18: 729738.
  • 13
    Li C, Lu SC, Hsieh PS et al. Distribution of human chemokine (C-X3-C) receptor 1 (CX3CR1) gene polymorphisms and haplotypes of the CC chemokine receptor 5 (CCR5) promoter in Chinese people, and the effects of CCR5 haplotypes on CCR5 expression. Int J Immunogenet 2005; 32: 99106.
  • 14
    Shieh B, Liau YE, Hsieh PS, Yan YP, Wang ST, Li C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol 2000; 12: 13111318.
  • 15
    Faure S, Meyer L, Genin E et al. Deleterious genetic influence of CX3CR1 genotypes on HIV-1 disease progression. J Acquir Immune Defic Syndr 2003; 32: 335337.
  • 16
    Singh KK, Hughes MD, Chen J, Spector SA. Genetic polymorphisms in CX3CR1 predict HIV-1 disease progression in children independently of CD4+ lymphocyte count and HIV-1 RNA load. J Infect Dis 2005; 191: 19711980.
  • 17
    Vidal F, Vilades C, Domingo P et al. Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele. J Acquir Immune Defic Syndr 2005; 40: 527531.
  • 18
    Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM. Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 1998; 273: 2379923804.
  • 19
    Shimizu N, Tanaka A, Oue A et al. Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV. AIDS 2009; 23: 761769.
  • 20
    Becker Y. The spreading of HIV-1 infection in the human organism is caused by fractalkine trafficking of the infected lymphocytes – a review, hypothesis and implications for treatment. Virus Genes 2007; 34: 93109.
  • 21
    Moatti D, Faure S, Fumeron F et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97: 19251928.
  • 22
    D'Aquila RT, Sutton L, Savara A, Hughes MD, Johnson VA. CCR5/delta(ccr5) heterozygosity: a selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype. NIAID AIDS Clinical Trials Group Protocol 241 Virology Team. J Infect Dis 1998; 177: 15491553.
  • 23
    Crudeli CM, Aulicino PC, Rocco CA, Bologna R, Mangano A, Sen L. Relevance of early detection of HIV type 1 SI/CXCR4-using viruses in vertically infected children. AIDS Res Hum Retroviruses 2012; 28: 685692.
  • 24
    Brumme ZL, Goodrich J, Mayer HB et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192: 466474.
  • 25
    Poveda E, Briz V, de Mendoza C et al. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 2007; 79: 10401046.
  • 26
    de Roda Husman AM, Koot M, Cornelissen M et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127: 882890.
  • 27
    Harrigan PR, Dong W, Wynhoven B, Mo T, Hall T, Galli R. The Performance of ReCall basecalling software for high-throughput HIV drug resistance basecalling using “in-house” methods. XIV International AIDS Conference. Spain, Barcelona, 2002 [Abstract #TuPeB4598].
  • 28
    Sierra-Madero J, Di Perri G, Wood R et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials 2010; 11: 125132.
  • 29
    Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803813.
  • 30
    Kristiansen TB, Knudsen TB, Ohlendorff S, Eugen-Olsen J. A new multiplex PCR strategy for the simultaneous determination of four genetic polymorphisms affecting HIV-1 disease progression. J Immunol Methods 2001; 252: 147151.
  • 31
    Parczewski M, Leszczyszyn-Pynka M, Kaczmarczyk M et al. Sequence variants of chemokine receptor genes and susceptibility to HIV-1 infection. J Appl Genet 2009; 50: 159166.
  • 32
    Casado C, Colombo S, Rauch A et al. Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS ONE 2010; 5: e11079.
  • 33
    Gaunt TR, Rodriguez S, Day IN. Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool “CubeX”. BMC Bioinformatics 2007; 8: 428.
  • 34
    McGovern RA, Thielen A, Portsmouth S et al. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr 2012; 61: 279286.
  • 35
    Shepherd JC, Jacobson LP, Qiao W et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis 2008; 198: 11041112.
  • 36
    Nozza S, Canducci F, Galli L et al. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. J Antimicrob Chemother 2012; 67: 12241227.
  • 37
    Simon B, Grabmeier-Pfistershammer K, Rieger A, Sarcletti M, Schmied B, Puchhammer-Stockl E. HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. AIDS 2010; 24: 20512058.
  • 38
    Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851861.
  • 39
    Fellay J, Shianna KV, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317: 944947.
  • 40
    McMichael AJ, Jones EY. Genetics. First-class control of HIV-1. Science 2010; 330: 14881490.
  • 41
    Deloukas P, Bentley D. The HapMap project and its application to genetic studies of drug response. Pharmacogenomics J 2004; 4: 8890.
  • 42
    Katzenstein TL, Eugen-Olsen J, Hofmann B et al. HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 1014.
  • 43
    Walli R, Reinhart B, Luckow B et al. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 229233.
  • 44
    Battiloro E, Andreoni M, Parisi SG et al. Distribution of the CCR5 delta32 allele in Italian HIV type 1-infected and normal individuals. AIDS Res Hum Retroviruses 2000; 16: 181182.
  • 45
    Hendrickson SL, Jacobson LP, Nelson GW et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. J Acquir Immune Defic Syndr 2008; 48: 263271.
  • 46
    Seclen E, Soriano V, Gonzalez MM et al. Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy. J Infect Dis 2011; 204: 139144.
  • 47
    Foussat A, Bouchet-Delbos L, Berrebi D et al. Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. Blood 2001; 98: 16781686.
  • 48
    Fernandez-Sender L, Alonso-Villaverde C, Rull A et al. A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study. AIDS Res Ther 2013; 10: 19.
  • 49
    Arenzana-Seisdedos F, Parmentier M. Genetics of resistance to HIV infection: role of co-receptors and co-receptor ligands. Semin Immunol 2006; 18: 387403.
  • 50
    Reiche EM, Bonametti AM, Voltarelli JC, Morimoto HK, Watanabe MA. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem 2007; 14: 13251334.